Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Thursday the availability of Trientine Hydrochloride Capsules USP in 250 mg.
The US Food and Drug Administration (FDA) approved Trientine Hydrochloride Capsules USP in 250 mg are a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules. The product can be stored at room temperature (20°C to 25°C or 68°F to 77°F) throughout the product shelf life of 24 months.
Dr. Reddy's Trientine Hydrochloride Capsules USP in 250 mg are available in 100 count bottles.
For the most recent 12 months ended December 2019, the Syprine brand and generic products had US sales of approximately USD94.2m MAT, according to IMS Health. Syprine is a trademark of Alton Pharma.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets